Zeffix

Zeffix

lamivudine

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Lamivudine
Indications/Uses
Chronic hepatitis B & evidence of HBV replication in patients ≥16 yr.
Dosage/Direction for Use
Administration
May be taken with or without food.
Contraindications
Special Precautions
Monitor serum LFTs (ALT & bilirubin levels) for at least 4 mth for evidence of recurrent hepatitis. Patients receiving immunosuppressive regimens; co-infected w/ HIV & currently or are planning to receive antiretroviral regimen. Transplantation recipient & advanced liver disease. Moderate to severe renal impairment. Pregnancy & lactation.
Adverse Reactions
Elevated ALT. Malaise & fatigue; resp tract infections; headache; abdominal discomfort & pain, nausea, vomiting & diarrhea. Rash; elevated CPK, muscle disorder (myalgia & cramps).
Drug Interactions
Increased exposure w/ trimethoprim/sulphamethoxazole. Increased Cmax of zidovudine. Inhibited intracellular phosphorylation of emtricitabine. Decreased exposure by sorbitol.
MIMS Class
Antivirals
ATC Classification
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Zeffix FC tab 100 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in